Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti‐BCMA‐targeted chimeric antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Baljevic, Muhamed, Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Lentzsch, Suzanne, Monge, Jorge, Kotb, Rami, Bahlis, Nizar J., White, Darrell, Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, DeCastro, Andrew, Van Domelen, Dane R., Zhang, Chris, Shah, Jatin J., Shacham, Sharon, Kauffman, Michael G., Bentur, Ohad S., Lipe, Brea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713049/
https://www.ncbi.nlm.nih.gov/pubmed/36467792
http://dx.doi.org/10.1002/jha2.572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713049/
https://www.ncbi.nlm.nih.gov/pubmed/36467792
http://dx.doi.org/10.1002/jha2.572

Ejemplares similares